UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000015925
Receipt number R000018046
Scientific Title The clinical study of correlation between cholesterol-lowering therapy and the progression of atherosclerosis in type 2 diabetes mellitus
Date of disclosure of the study information 2014/12/12
Last modified on 2016/09/14 11:41:13

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

The clinical study of correlation between cholesterol-lowering therapy and the progression of atherosclerosis in type 2 diabetes mellitus

Acronym

The clinical study of correlation between cholesterol-lowering therapy and the progression of atherosclerosis in type 2 diabetes mellitus

Scientific Title

The clinical study of correlation between cholesterol-lowering therapy and the progression of atherosclerosis in type 2 diabetes mellitus

Scientific Title:Acronym

The clinical study of correlation between cholesterol-lowering therapy and the progression of atherosclerosis in type 2 diabetes mellitus

Region

Japan


Condition

Condition

Atherosclerotic disease in type 2 diabetes mellitus

Classification by specialty

Endocrinology and Metabolism

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

Normal therapy group are intervened based on guidline, Japan Atherosclerosis Society (JAS) Guidelines for Prevention of Atherosclerotic Cardiovascular Diseases 2012, with the goal of lowering LDL-C to less than 120 mg/dl. Intensive therapy group, are intervened with the goal of lowering LDL-C to less than 80 mg/dl, with which it is reported that coronary plaque can regression by meta-analysis of clinical trial data. To establish the most effective lipid lowering therapy, this study will investigate the difference of the atherosclerotic progression between intensive therapy group and standard therapy group.

Basic objectives2

Safety,Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

1.the progression of intima-media thickness
2.the progression of pulse wave velocity

Key secondary outcomes



Base

Study type


Study design

Basic design

Parallel

Randomization

Randomized

Randomization unit


Blinding

Open -but assessor(s) are blinded

Control

Active

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

2

Purpose of intervention

Prevention

Type of intervention

Medicine Other

Interventions/Control_1

< intensive therapy group >
Based on guidline, Japan Atherosclerosis Society (JAS) Guidelines for Prevention of Atherosclerotic Cardiovascular Diseases 2012, with the goal of lowering LDL-C to less than 80 mg/dl.

Interventions/Control_2

< standard therapy group >
Based on guidline, JAS Guidelines 2012, with the goal of lowering LDL-C to less than 120 mg/dl.

Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

40 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

Type 2 Diabetes Mellitus patients whose LDL-C more than 120 mg/dL at the time of the clinical study start

Key exclusion criteria

1.The patients with cerebrovascular disease that developed recently, within 12 weeks.
2.The patients whose fasting triglyceride level>400 mg/dl
3.The patients who have histry of coronary heart disease
4.The patients with liver disfunction
5.The patients with renal disfunction, serum creatinine level is mere than 2 times of the facilities standard.
6.The patients with uncontroled respiratory failure, heart failure and arrhythmia etc.
7.The patients with Familial hypercholesterolemia.
8.The patients with alcoholicsm or medicinal intoxication.
9.The patients who are pregnant, lactating and may be pregnant.
10.The patients who doctors judge as unfitness.

Target sample size

200


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Takeshi Matsumura

Organization

Kumamoto University Hospital

Division name

Metabolism and Endocrinology

Zip code


Address

1-1-1 Honjo, Chuo, Kumamoto, 860-8556, Japan

TEL

096-373-5169

Email

takeshim@gpo.kumamoto-u.ac.jp


Public contact

Name of contact person

1st name
Middle name
Last name Takeshi Matsumura

Organization

Kumamoto University Hospital

Division name

Metabolism and Endocrinology

Zip code


Address

1-1-1 Honjo, Chuo, Kumamoto, 860-8556, Japan

TEL

096-373-5169

Homepage URL


Email

takeshim@gpo.kumamoto-u.ac.jp


Sponsor or person

Institute

Human Ethics Review Committee of Kumamoto University

Institute

Department

Personal name



Funding Source

Organization

This work was supported by a Grant-in-Aid for Scientific Research from the Japan Society for the Promotion of Scienc, Japan.

Organization

Division

Category of Funding Organization

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2014 Year 12 Month 12 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Enrolling by invitation

Date of protocol fixation

2014 Year 09 Month 30 Day

Date of IRB


Anticipated trial start date

2014 Year 10 Month 27 Day

Last follow-up date

2016 Year 04 Month 05 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2014 Year 12 Month 12 Day

Last modified on

2016 Year 09 Month 14 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000018046


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name